Drug Company Banks Expectation-Busting Profits for Q1 While Continuing to Hike Rx Prices During Pandemic

Johnson & Johnson kicked off the first quarterly earnings season of the year for Big Pharma Tuesday by reporting sales and revenue beats driven by price-hiking and anti-competitive behavior on prescription drugs.

Johnson & Johnson

These expectation-busting earnings come as the company has continued to hike prices on prescription drugs, despite a growing crisis of affordability and while receiving billions from taxpayers for the development and acquisition of a COVID-19 vaccine.

Johnson & Johnson

Stay tuned in the coming weeks as we continue to monitor Q1 earnings announcements from Big Pharma.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.